Moving towards efficient therapies in type 1 diabetes: To combine or not to combine?

Roep, 2004, Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes, Nat Rev Immunol, 4, 989, 10.1038/nri1502 von Herrath, 2005, Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity, J Exp Med, 202, 1159, 10.1084/jem.20051224 Pozzilli, 2002, The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention, Diabetes Metab Res Rev, 18, 257, 10.1002/dmrr.316 Gale, 2004, European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes, Lancet, 363, 925, 10.1016/S0140-6736(04)15786-3 Alleva, 2002, Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9–23) peptide, Diabetes, 51, 2126, 10.2337/diabetes.51.7.2126 Martin, 1991, Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects, Diabetologia, 34, 429, 10.1007/BF00403182 Pozzilli, 2000, No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group, Diabetologia, 43, 1000, 10.1007/s001250051482 Agardh, 2005, Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes, J Diabetes Complications, 19, 238, 10.1016/j.jdiacomp.2004.12.003 Raz, 2001, Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial, Lancet, 358, 1749, 10.1016/S0140-6736(01)06801-5 Herold, 2005, A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes, Diabetes, 54, 1763, 10.2337/diabetes.54.6.1763 Keymeulen, 2005, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes, N Engl J Med, 352, 2598, 10.1056/NEJMoa043980 Makhlouf, 2004, Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice, Transplantation, 77, 990, 10.1097/01.TP.0000118410.61419.59 Maki, 1992, Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum, Proc Natl Acad Sci U S A, 89, 3434, 10.1073/pnas.89.8.3434 Chatenoud, 1994, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice, Proc Natl Acad Sci U S A, 91, 123, 10.1073/pnas.91.1.123 von Herrath, 2002, Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance, J Immunol, 168, 933, 10.4049/jimmunol.168.2.933 Belghith, 2003, TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes, Nat Med, 9, 1202, 10.1038/nm924 Bisikirska, 2005, TCR stimulation with modified anti-CD3 mAb expands CD8+T cell population and induces CD8+CD25+Tregs, J Clin Invest, 115, 2904, 10.1172/JCI23961 Herold, 2003, Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala–Ala), J Clin Invest, 111, 409, 10.1172/JCI16090 Christen, 2001, A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis, J Immunol, 166, 7023, 10.4049/jimmunol.166.12.7023 Oikawa, 2003, Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice, J Immunol, 171, 5865, 10.4049/jimmunol.171.11.5865 Rothe, 1999, IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis, J Immunol, 163, 1230, 10.4049/jimmunol.163.3.1230 Zhang, 2003, Intramuscular injection of interleukin-10 plasmid DNA prevented autoimmune diabetes in mice, Acta Pharmacol Sin, 24, 751 Zanin-Zhorov, 2003, T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors, FASEB J, 17, 1567, 10.1096/fj.02-1139fje von Herrath, 2002, Vaccination to prevent type 1 diabetes, Expert Rev Vaccines, 1, 25, 10.1586/14760584.1.1.25 McDevitt, 2004, Specific antigen vaccination to treat autoimmune disease, Proc Natl Acad Sci U S A, 101, 14627, 10.1073/pnas.0405235101 Homann, 1999, Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference, J Immunol, 163, 1833, 10.4049/jimmunol.163.4.1833 Tang, 2006, Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice, Nat Immunol, 7, 83, 10.1038/ni1289 Bresson, 2006, A novel combination therapy in recent-onset autoimmune diabetes: Synergy of anti-CD3 and nasal proinsulin to induce regulatory T cells, J Clin Invest, 116, 1371, 10.1172/JCI27191 Bielekova, 2000, Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand, Nat Med, 6, 1167, 10.1038/80516 Li, 2001, Promotion of beta-cell regeneration by betacellulin in ninety percent-pancreatectomized rats, Endocrinology, 142, 5379, 10.1210/en.142.12.5379 von Herrath, 2005, E1-INT (Transition Therapeutics/Novo Nordisk), Curr Opin Investig Drugs, 6, 1037 Mallone, 2005, Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes, Am J Ther, 12, 534, 10.1097/01.mjt.0000178772.54396.38 Casares, 2002, Down-regulation of diabetogenic CD4+T cells by a soluble dimeric peptide-MHC class II chimera, Nat Immunol, 3, 383, 10.1038/ni770 Tang, 2004, In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes, J Exp Med, 199, 1455, 10.1084/jem.20040139 Suarez-Pinzon, 2005, Combination therapy with epidermal growth factor and gastrin increases {beta}-cell mass and reverses hyperglycemia in diabetic NOD mice, Diabetes, 54, 2596, 10.2337/diabetes.54.9.2596 Suarez-Pinzon, 2005, Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass, J Clin Endocrinol Metab, 90, 3401, 10.1210/jc.2004-0761 Ogawa, 2004, Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4, Diabetes, 53, 1700, 10.2337/diabetes.53.7.1700 Lampeter, 1998, The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group, Diabetes, 47, 980, 10.2337/diabetes.47.6.980 Kupila, 2003, Intranasally administered insulin intended for prevention of type 1 diabetes—a safety study in healthy adults, Diabetes Metab Res Rev, 19, 415, 10.1002/dmrr.397 Harrison, 2004, Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes, Diabetes Care, 27, 2348, 10.2337/diacare.27.10.2348